New report adds to growing evidence of iNKT cell therapy’s potential in solid tumors. NEW YORK, July 11, 2025 (GLOBE NEWSWIRE ...

BioNTech to wind down cell therapy manufacturing in Maryland, lay off 63 as it ends development of CAR-T drug in testicular cancer ...

Producing germ cells in vitro would open important new avenues for regenerative medicine, and obtaining alternative sources of pluripotent stem cells is desirable. In this regard, Geijsen et al ...

Shares of MiNK Therapeutics, Inc. (INKT) skyrocketed on Friday following the publication of a case from its clinical trial ...

Testicular cancer is not very common, but it deserves careful consideration because it can act rapidly in nonseminomatous germ cell tumours, which are more virulent than seminomas. Testicular cancer ...

Cancer does not develop overnight. It can take decades for cancer‐promoting changes in the genome to eventually lead to the ...

In the realm of cancer biology, the intersection of aging and cancer presents unique challenges, characterized by tumor ...

Most GCTs originate in the testes, and they account for approximately 95% of testicular cancers; however, GCTs occasionally originate in extragonadal sites such as the mediastinum or retroperitoneum.

AGC Biologics, your friendly CDMO expert, will commence cell therapy process development and clinical manufacturing services on July 1, 2025, at AGC Inc.’s Yokohama Technical Center, marking the ...